Because mTOR inhibitors in combination with CDK4/6 inhibitors was reported (Olmez et al., 2017), we thus investigated the effect of the combination of abemaciclib and gilteritinib in lung cancer cells. The gene discussed is CDK4; the disease is lung carcinoma.